<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>FDA press releases</title>
    <link>https://www.fda.gov/news-events/fda-newsroom/press-announcements</link>
    <description>Events collected by UnlimitedPipe 0.10.62</description>
    <generator>UnlimitedPipe 0.10.62</generator>
    <lastBuildDate>Tue, 17 Nov 2026 22:50:48 +0000</lastBuildDate>
    <item>
      <title>FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide</link>
      <guid isPermaLink="false">f400cf36028cf5e12873</guid>
      <pubDate>Tue, 17 Nov 2026 20:32:16 +0000</pubDate>
      <description>FDA today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health authorities around the world.</description>
    </item>
    <item>
      <title>FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer</link>
      <guid isPermaLink="false">21b844c97cda7d04edb0</guid>
      <pubDate>Tue, 17 Nov 2026 19:15:22 +0000</pubDate>
      <description>FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.</description>
    </item>
    <item>
      <title>FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk</link>
      <guid isPermaLink="false">ccb5f3bd8e918312100b</guid>
      <pubDate>Mon, 09 Nov 2026 22:15:46 +0000</pubDate>
      <description>FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.</description>
    </item>
    <item>
      <title>FDA Launches Expedited IND Pilot, Begins Accepting Applications</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-launches-expedited-ind-pilot-begins-accepting-applications</link>
      <guid isPermaLink="false">1da4ed21ef2c58db3b1e</guid>
      <pubDate>Tue, 15 Sep 2026 13:53:31 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today announced the final design of the Expedited Investigational New Drug (IND) Pilot.</description>
    </item>
    <item>
      <title>FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma</link>
      <guid isPermaLink="false">d2b3d8e893100c0b06fe</guid>
      <pubDate>Thu, 05 Nov 2026 22:30:38 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherap</description>
    </item>
    <item>
      <title>FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-takes-steps-maintain-newborn-access-life-saving-starter-nutrition-products</link>
      <guid isPermaLink="false">6b0ab710c0f28efb9848</guid>
      <pubDate>Fri, 04 Sep 2026 20:18:49 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today announced it is taking action, consistent with the Trump administration’s commitment to protecting vulnerable patients and maintaining access to critical medical products, to help address a potential supply gap of neonatal starter parenteral nutrition (PN)</description>
    </item>
    <item>
      <title>FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-provides-clarity-support-cell-and-gene-therapy-development-and-quality</link>
      <guid isPermaLink="false">700b65cf6a99ac297f11</guid>
      <pubDate>Mon, 02 Nov 2026 13:56:06 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products meet potency standards.</description>
    </item>
    <item>
      <title>FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis</link>
      <guid isPermaLink="false">2d010ab2f631c2a8efc0</guid>
      <pubDate>Fri, 30 Oct 2026 20:32:08 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).</description>
    </item>
    <item>
      <title>FDA Launches New Program to Advance Neuroscience Medical Product Development</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-launches-new-program-advance-neuroscience-medical-product-development</link>
      <guid isPermaLink="false">37355ddec449b227384b</guid>
      <pubDate>Thu, 22 Oct 2026 16:58:19 +0000</pubDate>
      <description>FDA announces the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments.</description>
    </item>
    <item>
      <title>FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment</link>
      <guid isPermaLink="false">3537e6a8ec61dbd8edee</guid>
      <pubDate>Tue, 20 Oct 2026 19:40:38 +0000</pubDate>
      <description>FDA today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.</description>
    </item>
    <item>
      <title>FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-once-weekly-generic-hormone-therapy-patch-women</link>
      <guid isPermaLink="false">c401c8b6324d86aff1fd</guid>
      <pubDate>Tue, 20 Oct 2026 15:57:36 +0000</pubDate>
      <description>Today, the U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week.</description>
    </item>
    <item>
      <title>FDA Issues Final Guidance on Prescription Drug Apps and Software</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-issues-final-guidance-prescription-drug-apps-and-software</link>
      <guid isPermaLink="false">b1a2f25d7a29db048295</guid>
      <pubDate>Tue, 20 Oct 2026 13:03:14 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines.</description>
    </item>
    <item>
      <title>FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-immunotherapy-may-allow-certain-patients-rectal-cancer-avoid-chemotherapy-radiation-and</link>
      <guid isPermaLink="false">e1875b9da3e0c616dee6</guid>
      <pubDate>Mon, 19 Oct 2026 16:19:38 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.</description>
    </item>
    <item>
      <title>FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease</link>
      <guid isPermaLink="false">150d6d03920e594d234e</guid>
      <pubDate>Wed, 14 Oct 2026 15:50:52 +0000</pubDate>
      <description>The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.</description>
    </item>
    <item>
      <title>FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-certain-people-bcg-unresponsive-bladder-cancer</link>
      <guid isPermaLink="false">7f9cc3c94d1d0a86bf82</guid>
      <pubDate>Wed, 14 Oct 2026 15:14:51 +0000</pubDate>
      <description>FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer</description>
    </item>
    <item>
      <title>FDA Seeks Public Input to Support Ibogaine Research</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research</link>
      <guid isPermaLink="false">19c220a9d4f9549c8c5d</guid>
      <pubDate>Mon, 05 Oct 2026 13:02:06 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today announced a request for information (RFI) describing approaches the agency is considering for the design of early-phase clinical trials of ibogaine drug products and seeking public input on those approaches.</description>
    </item>
    <item>
      <title>FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia</link>
      <guid isPermaLink="false">b0ed8407f4f141e6cb4d</guid>
      <pubDate>Wed, 19 Aug 2026 21:33:10 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first-ever treatment for adults and children 8 years of age and older with glycogen storage disease type Ia (GSDIa)</description>
    </item>
    <item>
      <title>FDA Approves First Heart Valve Designed to Grow with Children</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-heart-valve-designed-grow-children</link>
      <guid isPermaLink="false">6101514d9e0c5a5435e4</guid>
      <pubDate>Thu, 01 Oct 2026 19:02:08 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease.</description>
    </item>
    <item>
      <title>FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-launches-nationwide-effort-expand-scientific-expertise-and-consumer-voices-advisory-committees</link>
      <guid isPermaLink="false">5ecf21fa709c48d6cf0a</guid>
      <pubDate>Wed, 30 Sep 2026 13:26:33 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today announced a broad, nationwide recruitment effort to expand the range of qualified voices and perspectives on its advisory committees— the independent bodies that inform some of the most consequential decisions in American public health.</description>
    </item>
    <item>
      <title>FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-seeks-public-feedback-inform-regulatory-approach-generative-ai-enabled-medical-devices</link>
      <guid isPermaLink="false">41631d700bad63976396</guid>
      <pubDate>Tue, 18 Aug 2026 14:10:03 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today issued a discussion paper on considerations for the regulation of generative artificial intelligence (GenAI)-enabled medical devices, seeking feedback from interested parties on risk assessment, premarket evaluation, postmarket monitoring, and other topics</description>
    </item>
    <item>
      <title>FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-investigation-leads-charges-against-two-indian-nationals-involved-transnational-counterfeit-drug</link>
      <guid isPermaLink="false">9ab28dfd48dbf2e949dc</guid>
      <pubDate>Tue, 29 Sep 2026 21:01:07 +0000</pubDate>
      <description>The U.S. Attorney’s Office for the Middle District of Florida and the Criminal Division of the U.S. Department of Justice today announced federal charges against Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals.</description>
    </item>
    <item>
      <title>FDA Approves First Treatment for MCT8 Deficiency</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-mct8-deficiency</link>
      <guid isPermaLink="false">385ab3805bb9218964d8</guid>
      <pubDate>Mon, 28 Sep 2026 21:43:18 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patient</description>
    </item>
    <item>
      <title>FDA intends to evaluate changes to the PMTA regulatory framework</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-intends-evaluate-changes-pmta-regulatory-framework</link>
      <guid isPermaLink="false">0e002a5f7ee86f6ed5fe</guid>
      <pubDate>Mon, 28 Sep 2026 21:00:01 +0000</pubDate>
      <description>FDA is carefully reviewing its experience implementing the Premarket Tobacco Product Application (PMTA) rule, as well as recent judicial developments, including a federal lawsuit filed in the U.S. District Court for the Northern District of Texas challenging the current regulatory framework.</description>
    </item>
    <item>
      <title>FDA Issues Emergency Use Authorization for Drug to Prevent New World Screwworm in Multiple Species, Including Sheep, Cattle, Goats, and Swine</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-prevent-new-world-screwworm-multiple-species-including</link>
      <guid isPermaLink="false">1afdd1e92eab6afec938</guid>
      <pubDate>Fri, 07 Aug 2026 13:00:09 +0000</pubDate>
      <description>FDA today issued an Emergency Use Authorization (EUA) for CLiK Extra (dicyclanil topical suspension) wound spray for application on or around wounds for the prevention of New World screwworm (NWS) infestations (myiasis).</description>
    </item>
    <item>
      <title>FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma</link>
      <guid isPermaLink="false">341373f2ba931ac13863</guid>
      <pubDate>Thu, 06 Aug 2026 19:56:59 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced, refractory melanoma.</description>
    </item>
    <item>
      <title>Federal Court Enters Consent Decree Against Gold Star Distribution, Inc. Following Persistent Insanitary Warehouse Conditions</title>
      <link>http://www.fda.gov/news-events/press-announcements/federal-court-enters-consent-decree-against-gold-star-distribution-inc-following-persistent</link>
      <guid isPermaLink="false">36b858f469d029d37143</guid>
      <pubDate>Wed, 23 Sep 2026 19:50:17 +0000</pubDate>
      <description>A U.S. Food and Drug Administration investigation resulted in a federal court order, dated Sept. 21, 2026, stopping a warehouse operator from distributing FDA-regulated products including food, drugs, medical devices, and cosmetics until it fixes its operations to meet federal legal requirements.</description>
    </item>
    <item>
      <title>FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-updates-regulations-advance-innovative-alternatives-animal-testing</link>
      <guid isPermaLink="false">2b3428bb22bee286721a</guid>
      <pubDate>Mon, 21 Sep 2026 12:58:34 +0000</pubDate>
      <description>The FDA today issued a direct final rule that updates its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products intended for human use before they’re tried in humans.</description>
    </item>
    <item>
      <title>FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-pediatric-patients-sanfilippo-syndrome-type</link>
      <guid isPermaLink="false">237155efbd3ff869a34c</guid>
      <pubDate>Thu, 17 Sep 2026 18:26:43 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.</description>
    </item>
    <item>
      <title>FDA Grants Accelerated Approval to a New Breast Cancer Treatment</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment</link>
      <guid isPermaLink="false">657a5d0b623029b8b1b6</guid>
      <pubDate>Fri, 04 Sep 2026 19:38:04 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new treatments to patients who need them.</description>
    </item>
    <item>
      <title>FDA Approves First Drug to Treat Alexander Disease</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease</link>
      <guid isPermaLink="false">dc477c4fcae43ad7141e</guid>
      <pubDate>Thu, 03 Sep 2026 19:48:27 +0000</pubDate>
      <description>The U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients.</description>
    </item>
    <item>
      <title>FDA Issues Emergency Use Authorization for Drugs to Prevent and Treat New World Screwworm in Dogs and Cats</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drugs-prevent-and-treat-new-world-screwworm-dogs-and-cats</link>
      <guid isPermaLink="false">67277b3c99352891d965</guid>
      <pubDate>Thu, 03 Sep 2026 15:01:02 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Capstar (nitenpyram) tablets and revised the EUA for Nitenpyram Tablets, the generic version of Capstar</description>
    </item>
    <item>
      <title>FDA Seeks Public Input to Advance Development of Botanical Drug Products</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-advance-development-botanical-drug-products</link>
      <guid isPermaLink="false">23efa902d6774f033313</guid>
      <pubDate>Thu, 03 Sep 2026 12:52:49 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today announced a request for information (RFI) to gather public input on opportunities to advance the development of botanical drug products.</description>
    </item>
    <item>
      <title>FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder</link>
      <guid isPermaLink="false">31262e5d4b66ca88442d</guid>
      <pubDate>Fri, 28 Aug 2026 21:22:41 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.</description>
    </item>
    <item>
      <title>FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults</link>
      <guid isPermaLink="false">79cf79dc092b23fe3bd6</guid>
      <pubDate>Thu, 27 Aug 2026 19:11:11 +0000</pubDate>
      <description>The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets for the treatment of dermatomyositis in adults.</description>
    </item>
    <item>
      <title>FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in Cattle</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-generic-drug-prevent-new-world-screwworm-cattle</link>
      <guid isPermaLink="false">3b06b5752d0a095d212d</guid>
      <pubDate>Thu, 27 Aug 2026 16:55:38 +0000</pubDate>
      <description>FDA issues Emergency Use Authorization (EUA) for Bimectin (ivermectin) injection for the prevention of New World screwworm (NWS) infestations (myiasis) in cattle when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound.</description>
    </item>
    <item>
      <title>FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer</link>
      <guid isPermaLink="false">79281ba0fec0b4b40272</guid>
      <pubDate>Wed, 26 Aug 2026 14:33:36 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.</description>
    </item>
    <item>
      <title>FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-authorizes-first-wearable-device-continuously-monitors-both-ketone-levels-and-blood-sugar</link>
      <guid isPermaLink="false">885ebe2ff0c3c2bd7414</guid>
      <pubDate>Tue, 25 Aug 2026 18:21:22 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes.</description>
    </item>
    <item>
      <title>FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-authorizes-first-its-kind-robotic-blood-draw-device</link>
      <guid isPermaLink="false">7f2475f893153d4a1e80</guid>
      <pubDate>Wed, 19 Aug 2026 16:48:13 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today authorized the Aletta, the first standalone robotic device that can draw blood from a patient’s arm without hands-on operator intervention.</description>
    </item>
    <item>
      <title>FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies</title>
      <link>http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-treat-new-world-screwworm-dogs-and-puppies</link>
      <guid isPermaLink="false">83edf07b8bd0cea605b4</guid>
      <pubDate>Thu, 13 Aug 2026 17:02:58 +0000</pubDate>
      <description>The U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Simparica TRIO (sarolaner, moxidectin, and pyrantel chewable tablets) for the treatment of New World screwworm (NWS) infestations (myiasis) in dogs and puppies.</description>
    </item>
  </channel>
</rss>
